[
  {
    "ts": null,
    "headline": "Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation",
    "summary": "Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 2024 Board authorizes stock repurchase program of up to $100 million Reaffirms cash runway guidance through the second half of 2028 NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today provided an update on its collaboration with",
    "url": "https://finnhub.io/api/news?id=fc4e4d628d72bba92164e0051c30e1096cf67bb94d52395b6bd763810dd242fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758144600,
      "headline": "Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation",
      "id": 136797751,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 2024 Board authorizes stock repurchase program of up to $100 million Reaffirms cash runway guidance through the second half of 2028 NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today provided an update on its collaboration with",
      "url": "https://finnhub.io/api/news?id=fc4e4d628d72bba92164e0051c30e1096cf67bb94d52395b6bd763810dd242fa"
    }
  },
  {
    "ts": null,
    "headline": "MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response",
    "summary": "Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.",
    "url": "https://finnhub.io/api/news?id=4e8cda0cb7b88c74d1caf45046acd4fed2d44f4bfb67ad1bd11b03f4caed8373",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758121440,
      "headline": "MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response",
      "id": 136789966,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.",
      "url": "https://finnhub.io/api/news?id=4e8cda0cb7b88c74d1caf45046acd4fed2d44f4bfb67ad1bd11b03f4caed8373"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Cheap Doesn't Mean Good",
    "summary": "Pfizer faces a significant patent cliff, pricing reforms, and limited financial flexibility from high debt, all threatening future earnings growth. Learn more about PFE stock here.",
    "url": "https://finnhub.io/api/news?id=656cd7e5ccf99b536d08e55de80ef6d32b0103b7a947102e7f1a50c8e21b7bb7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758114057,
      "headline": "Pfizer: Cheap Doesn't Mean Good",
      "id": 136790553,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288428941/image_1288428941.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer faces a significant patent cliff, pricing reforms, and limited financial flexibility from high debt, all threatening future earnings growth. Learn more about PFE stock here.",
      "url": "https://finnhub.io/api/news?id=656cd7e5ccf99b536d08e55de80ef6d32b0103b7a947102e7f1a50c8e21b7bb7"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Pfizer Shares After Trump Officials Link COVID Vaccines to Child Deaths",
    "summary": "If you have been eyeing Pfizer's stock, you are not alone in wondering whether this healthcare giant's shares might be at an inflection point. The last few years have been a wild ride for investors, especially coming off the pandemic era spotlight. At a recent closing price of $23.90, Pfizer's share price performance has been underwhelming: down 3.3% in the past week, 4.9% in the last 30 days, and a steeper 14.3% slide over the past year. Looking back even further, the five-year return stands...",
    "url": "https://finnhub.io/api/news?id=41c81784c5c40503baf665faf90cc1138567122761cd5072e638fdfe431cf01c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758112617,
      "headline": "Assessing Pfizer Shares After Trump Officials Link COVID Vaccines to Child Deaths",
      "id": 136787612,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "If you have been eyeing Pfizer's stock, you are not alone in wondering whether this healthcare giant's shares might be at an inflection point. The last few years have been a wild ride for investors, especially coming off the pandemic era spotlight. At a recent closing price of $23.90, Pfizer's share price performance has been underwhelming: down 3.3% in the past week, 4.9% in the last 30 days, and a steeper 14.3% slide over the past year. Looking back even further, the five-year return stands...",
      "url": "https://finnhub.io/api/news?id=41c81784c5c40503baf665faf90cc1138567122761cd5072e638fdfe431cf01c"
    }
  }
]